The mammary gland is a dynamic organ that undergoes significant developmental changes during pregnancy, lactation, and involution. Mammary gland cancer may develop through dysregulation of self-renewal pathways of normal mammary stem cells. The regulation of the self-renewal, differentiation, and migration of mammary stem cells and their progenitors that are localized in the mammary glands appears to be assumed through distinct developmental signalling pathways such as hormones, EGF, hedgehog, Wnt/β-catenin, Notch, and Bmi-1. Several tumour suppressors inhibit regenerative capacity by promoting cell death or senescence in stem cells. The breast cancer susceptibility gene (*BRCA1*) is a tumour suppressor gene expressed in many nuclear processes, including stem cell regulation, DNA damage repair, recombination, transcription, ubiquitination, cell cycle checkpoint enforcement, and centrosome regulation. *BRCA1*is mutated in about one-half of all hereditary mammary gland cancer cases, and its expression is frequently decreased in sporadic cancers. Women with hereditary mammary gland and ovarian cancer due to *BRCA1*mutations are born with a mutation in one *BRCA1*allele, but only develop cancer after mutation or allelic loss of the other *BRCA1*allele. *BRCA1*plays a critical role in the differentiation of ER-negative stem/progenitor cells from ER-positive luminal cells. Defects of the *BRCA1*gene may result in the accumulation of genetically unstable mammary gland stem cells, providing prime targets for further carcinogenic events, because *BRCA1*also plays a role in DNA repair. Our study indicates that restoration of normal wild-type *BRCA1*expression levels in many mammary gland cancers may inhibit tumours by a genetic correction strategy, wherein the loss of *BRCA1*expression contributes to tumorigenesis.
